INIFY LABORATORIES Aktie

 

Reference is made to the stock exchange announcement made by Inify Laboratories AB (the "Company") on 4 December 2025 regarding the resolution to issue 26,266,866 new shares in a private placement (the "Private Placement Shares") and 2,304,563 new shares in a repair issue (the "Repair Issue Shares"). The share capital increase pertaining to the issuance of the Private Placement Shares and the Repair Issue Shares has now been registered with the Swedish Companies Registration Office (Sw. Bolagsverket). The Company's new registered share capital is SEK 6,945,746.803089, divided on 107,474,...

US88706T1088 KYG8918W1069 VGG878801114 CA87357T3001 FI4000176557 BMG3775G1539 CNE1000004H7 CNE1000001C4 HK0000981941 CNE100007F72 JP3535800001 US8740361063 KYG910191363 HK0000827664 BRUSIMACNOR3 ID1000191109 SE0017769136 SGXE24586385 GB00BN4M3M55 ES0105670006 GB00BMBVXB73 ES0105650008 ES0105650073 KYG0958D1060 CA88089G2027 CNE100005RV4 GB00BNBQZW49 AU000000EGH7 US84612H1068 US33744V1035 CA00686A1084 ID1000058407 AU0000312480 SE0017616006 SE0010102095 US69355M1071 US96145W1036 US2316472073 CNE100007DW8 ES0105618005 KYG2050P1028 AU0000150351 SE0017082514 GB00BLR8T846 CA59100N1042 KYG2117N1088 AU000000LIN6 HK0345001611 GB0001482891 AU000000DCC9 SG1J24887775 CNE100006JG0 JP3960000002 CA58046P1080 CH0210362643 IT0005678104 ZAE000167391 PLRNDCB00011 CA37150L1031 CA3638821015 ID1000100209 US9426221019 BMG8403G1033 CA60256C2076 BMG2118X1056 PLBRTZM00010 PLYLWHT00012 CA18914M2076 US9396531017 CNE100003F19 SE0017486103 KYG5244R1083 US98419J3059...

Stockholm, Sweden, 30 January 2026, Reference is made to the stock exchange announcement made by Inify Laboratories AB (publ.) (the "Company") on 27 January 2026 regarding allocation of new shares to primary insiders in the repair issue announced by the Company on 9 December 2025 (the "Repair Issue"). The number of shares allocated to board member Martin Ingvar was incorrectly stated as 67,132 in the announcement of 27 January 2026. The correct number of shares allocated to Ingvar in the Repair Issue is 67,372. Consequently, Ingvar will, subject to the completion of the Repair Issue, own...

Stockholm, Sweden, 27 January 2026; Inify Laboratories AB (publ.) (the "Company") announces that the below primary insiders were allocated new shares at the subscription price in the repair issue announced by the Company on 9 December 2025 (the "Repair Issue"), as further specified in the attached notification forms:   -          Monsun AS, a company closely associated with board member Magne Jordanger, has been allocated 898,204 Shares in the Repair Issue. Magne Jordanger will, through the companies Monsun AS and Gallivant S.a.r.l. and subject to completion of the Repair Issue and...

STOCKHOLM – 27 January 2026 – Reference is made to the stock exchange announcement made by Inify Laboratories AB (the "Company") on 12 January 2026 regarding the commencement of the subscription period in a fully guaranteed repair issue of 2,304,563 new shares (the "Offer Shares") in the Company (the "Repair Issue"), at an offer price of NOK 3.50 per Offer Share (the "Offer Price"), with gross proceeds of approximately NOK 8 million. The subscription period in the Repair Issue expired on 26 January 2026 at 16:30 hours (CET). By the end of the subscription period, the Company had received...

STOCKHOLM – 12 January 2026 – Reference is made to the stock exchange announcement made by Inify Laboratories AB (the "Company") on 19 December 2025 regarding the final results of the fully guaranteed private placement (the "Private Placement"). Further, reference is made to the stock exchange announcement made by the Company on 17 December 2025 and previous announcements regarding the fully guaranteed repair issue of 2,304,563 new shares (the "Repair Issue"). The Repair Issue will be directed pro-rata towards existing shareholders that did not participate in the Private Placement and who...

Stockholm – 19 December 2025 – Inify Laboratories AB (publ) (the "Company") announces that the below primary insider was allocated new shares at the subscription price in the private placement announced by the Company on 9 December 2025 (the "Private Placement"), as further specified in the attached notification forms: -          Gallivant S.à r.l. and Monsun AS, companies closely associated with board member Magne Jordanger, have been allocated 17,167,701 and 3,347,788 new shares, respectively, in the Private Placement (in aggregate: 20,515,489 new shares). Gallivant S.à r.l. and...

STOCKHOLM – 19 December 2025 – Reference is made to the stock exchange announcement made by Inify Laboratories AB (publ) (the "Company") on 9 December 2025 regarding the fully guaranteed private placement of new shares in the Company (the “Private Placement Shares”) with gross proceeds of approximately NOK 92 million with a minimum subscription per subscriber of the NOK equivalent of EUR 100,000, directed pro-rata towards existing shareholders holding more than 1,000,000 shares in the Company (the “Private Placement”), and the fully guaranteed repair issue of approximately NOK 8 million (...

Reference is made to the stock exchange announcement published today, 17 December 2025, regarding the preliminary results of the private placement of new shares (the "Private Placement") in Inify Laboratories AB (publ) (the "Company"), where it was announced that the Company will carry out a fully guaranteed repair issue of new shares in the Company with gross proceeds of approximately NOK 8 million (the "Repair Issue").   The Repair Issue will, subject to applicable securities law, be directed pro-rata towards all existing shareholders in the Company, other than the shareholders...

STOCKHOLM – 17 December 2025 – Reference is made to the stock exchange announcement made by Inify Laboratories AB (the "Company") on 9 December 2025 regarding the fully guaranteed private placement of new shares in the Company (the “Private Placement Shares”) with gross proceeds of approximately NOK 92 million with a minimum subscription per subscriber of the NOK equivalent of EUR 100,000, directed pro-rata towards existing shareholders holding more than 1,000,000 shares in the Company (the “Private Placement”), and the fully guaranteed repair issue of approximately NOK 8 million (the “...

Stockholm, Sweden, December 16, 2025; Inify Laboratories AB (publ.) has been notified that the following transactions have been completed by a primary insider in Inify; Fredrik Palm, CEO and primary insider in Inify, has acquired 12,000 shares in Inify at an average price of NOK 3.383 per share on December 16th. After the transaction, Palm holds 103,049 shares in the company.     This information is subject to the disclosure requirements pursuant to the EU Market Abuse Regulation (EU 596/2014 article 19) and section 5-12 of the Norwegian Securities Trading Act.   For further...

STOCKHOLM – 9 December 2025 – Reference is made to the stock exchange announcement made by Inify Laboratories AB (the “Company”) on 12 November 2025, regarding a proposed fully guaranteed share issue generating gross proceeds of approximately NOK 100 million, and the extraordinary general meeting held 4 December 2025 which resolved on the proposed share issue. The general meeting resolved to launch the fully guaranteed private placement of new shares (the “Private Placement Shares”) with gross proceeds of approximately NOK 92 million with a minimum subscription per subscriber of the NOK...

Today, December 4, 2025, an extraordinary general meeting was held in INIFY Laboratories AB, reg. no. 559345-4431 (the "Company"). At the meeting, 66,655,976 shares were represented, corresponding to 84.5 per cent of the total number of shares and votes in the Company. Below follows a summary of the resolution adopted at the meeting. Resolution on directed share issues The general meeting resolved, in accordance with the board of directors' proposal, on a directed issue of shares to SB1 Markets AS for onward transfer to major shareholders in the Company (the "Private Placement") and...

STOCKHOLM – December 3, 2025 - The board of directors of Inify Laboratories AB ("Inify" or the "Company") announces its intention to postpone the last date of payment in the Company's proposed share issues announced on November 12, 2025, (the "Private Placement" and the "Repair Issue" respectively). The final payment date is intended to be postponed to March 25, 2026, providing shareholders with additional time to procure the necessary funds to participate in the Private Placement and the Repair Issue. The postponement of the last date of payment will also affect the expected final date...

Stockholm – November 12, 2025 - Inify Laboratories AB (publ), a unique laboratory service that provides cancer diagnostics within pathology, hereby invites its shareholders to Extraordinary General Meeting on December 4, 2025. Please find attached the invitation including attachment, agenda and details on how to register and vote. The invitation is also available on the company's website: www.inify.com (https://inify-my.sharepoint.com/personal/ann-charlotte_linderoth_inify_com/Documents/INIFY%20Laboratories%20AB/IR%20och%20regulatoriskt/Bolagsstämma/Extra%20bolagsstämma%202024-12-06/...

STOCKHOLM – November 12, 2025 - Inify Laboratories AB ("Inify" or the "Company") will in a separate press release call for an extraordinary general meeting (the "EGM") to be held on December 4, 2025 at 10:00 CET to resolve on a fully guaranteed share issue of a total of 28,571,429 new shares generating gross proceeds of approximately NOK 100 million. The board of directors' reasons for proposing the equity issue are to ensure financial stability and persistence. This is due to a slight delay in the fit-out project and larger-than-expected investments related to the establishment in the...

In connection with the publication of the company's Q3 2025 Financial Report, it was discovered that the amount for personnel costs in the parent company's income statement was incorrect. The company is therefore making a correction to the parent company's income statement. STOCKHOLM – October 29, 2025 - Inify Laboratories, a unique laboratory service that provides cancer diagnostics within pathology, expanded its service offering during the third quarter with the addition of a second diagnostic area: gastroenterology. In September, the company launched gastrointestinal diagnostics...

STOCKHOLM – October 29, 2025 - Inify Laboratories, a unique laboratory service that provides cancer diagnostics within pathology, expanded its service offering during the third quarter with the addition of a second diagnostic area: gastroenterology. In September, the company launched gastrointestinal diagnostics services in Sweden, successfully diagnosing its first patient samples. “This marks the starting point for addressing a market with very large sample volumes and enormous capacity needs. In Sweden alone, hundreds of thousands of endoscopy examinations are performed annually, many...

Inify Laboratories has achieved a measurable impact in prostate cancer diagnostics. Official statistics from the Swedish Cancer Registry show that the company has shortened waiting times for prostate biopsies by several weeks for each patient since entering the market. [image]Fredrik Palm, CEO of Inify Laboratories, emphasised this achievement during a panel talk on the company's second quarter, moderated by Olie Eikeland. “It's all about pathways. By supporting the entire clinical pathway for prostate cancer – from the urology department to the pathology department – we generate...

Stockholm, Sweden, August 29, 2025; Inify Laboratories AB (publ.) has been notified that the following transactions have been completed by a primary insider in Inify; Martin Ingvar, board member and primary insider in Inify, has acquired 9,500 shares in Inify at an average price of SEK 5.50 per share on August 28th. After the transaction, Ingvar holds 186,063 shares.     This information is subject to the disclosure requirements pursuant to the EU Market Abuse Regulation (EU 596/2014 article 19) and section 5-12 of the Norwegian Securities Trading Act.   For further...